Trials / Active Not Recruiting
Active Not RecruitingNCT04958811
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
A Phase II Open-label Multi-cohort Study Evaluating the Efficacy of Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Georgetown University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of tiragolumab with atezolizumab and bevacizumab in previously-treated advanced non-squamous NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tiragolumab | 600mg IV administered every 3 weeks. |
| DRUG | Atezolizumab | 1200mg IV administered every 3 weeks. |
| DRUG | Bevacizumab | 15mg/kg IV administered every 3 weeks. |
Timeline
- Start date
- 2021-12-21
- Primary completion
- 2026-07-01
- Completion
- 2026-12-01
- First posted
- 2021-07-12
- Last updated
- 2026-01-26
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04958811. Inclusion in this directory is not an endorsement.